A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Condition: HIV-1 Infection Interventions: Drug: DOR/ISL; Drug: BIC/FTC/TAF; Drug: Placebo to BIC/FTC/TAF; Drug: Placebo to DOR/ISL Sponsor: Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials
The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection
Condition: HIV-1-infection Intervention: Drug: BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 4, 2022 Category: Research Source Type: clinical trials
